Rising costs in today’s healthcare marketplace have driven employers to find ways to curtail expenses without adversely affecting their employees. Self-funding is one solution that enables employers to provide quality health benefits while realizing cost savings, giving them the opportunity to tailor coverage through specialty carve-outs.

This piece examines the challenges this presents due to the ability to exclude specialty drugs, which means that employer sponsors are therefore using a third-party to administer an alternative funding program (AFP). Download the white paper to learn how this problem will continue to gain momentum in 2023, impacting patient assistance programs this year and beyond.